Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharmaceuticals has signed a commercialization, manufacturing and supply pact with Teva Pharmaceutical for Gemcitabine HCI for Injection.
Subscribe to our email newsletter
As per the terms of the agreement, Teva Pharma has licensed APP Pharma to market Gemcitabine HCI for Injection in 200mg and 1g single dose vials during the 180 day Hatch Waxman exclusivity period.
Further, APP Pharma is intending to introduce Gemcitabine HCI for Injection soon.
APP Pharma president and CEO John Ducker said the agreement between the two companies demonstrates APP’s willingness and versatility to enter into collaborative agreements to ensure patient access to affordable cancer treatments.